Cranbury Pharmaceuticals, LLC won FDA approval for its ANDA201295 generic of Hydrocodone Bitartrate and Acetaminophen, marking the company's entry into a competitive market that may exert downward pressure on pricing and erode the market share of existing branded formulations.